Posted inClinical Updates Wellness & Lifestyle
ADAGIO Trial Illuminates Adavosertib’s Potential in Recurrent Uterine Serous Carcinoma Amidst Safety Challenges
The ADAGIO phase IIb study assessed adavosertib in recurrent uterine serous carcinoma post-platinum therapy, revealing modest efficacy and significant toxicity, with biomarker trends suggesting CCNE1/cyclin E1 as potential response predictors.